PINK:SGPYY
The Sage Group plc Stock News
$55.04
-0.0100 (-0.0182%)
At Close: Jun 21, 2024
LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics
LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics
Allegations Against Sage Therapeutics, Inc.: Schall Law Firm Initiates Probe And Encourages Impacted Investors To Reach Out
07:45pm, Tuesday, 11'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics
Sage Therapeutics' rare disease drug meets main goal in mid-stage study
06:51am, Tuesday, 11'th Jun 2024
Sage Therapeutics said on Tuesday its experimental drug met the main goal of a mid-stage study in patients with a type of rare disease known as Huntington's disease.
Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington's Disease
06:30am, Tuesday, 11'th Jun 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics announced today topline results from the Phase 2 SURVEYOR Study. The study met its primary endpoint demonstrating a statistically significant diffe
LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
Allegations Made Against Sage Therapeutics, Inc.: Schall Law Firm Commences Probe And Calls On Impacted Investors To Engage
11:00am, Saturday, 08'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
Accusations Against Sage Therapeutics, Inc.: Schall Law Firm Begins Investigation And Invites Affected Investors To Connect
06:15pm, Friday, 07'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
Allegations Against Sage Therapeutics, Inc.: Schall Law Firm Initiates Inquiry and Encourages Impacted Investors to Reach Out
01:00pm, Thursday, 06'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
Sage Therapeutics, Inc. Allegations: Schall Law Firm Undertakes Investigation and Urges Affected Investors to Connect
01:45pm, Wednesday, 05'th Jun 2024
LOS ANGELES, CA / ACCESSWIRE / June 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
06:30am, Wednesday, 05'th Jun 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will
LOS ANGELES, CA / ACCESSWIRE / June 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
LOS ANGELES, CA / ACCESSWIRE / June 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
LOS ANGELES, CA / ACCESSWIRE / June 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
LOS ANGELES, CA / ACCESSWIRE / May 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sage Therapeutics,
